HEADER HYDROLASE 24-OCT-20 7ARF TITLE STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO THIOGLUCOSE. COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: 3CL-PRO,3CLP,MAIN PROTEASE,MPRO,NON-STRUCTURAL PROTEIN 5, COMPND 5 NSP5,SARS CORONAVIRUS MAIN PROTEINASE; COMPND 6 EC: 3.4.22.69; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: REP, 1A-1B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS SARS-COV-2, MPRO, COVID-19, PEPTIDE BINDING PROTEIN, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR S.GUENTHER,P.REINKE,D.OBERTHUER,O.YEFANOV,L.GELISIO,H.GINN,J.LIESKE, AUTHOR 2 M.DOMARACKY,W.BREHM,A.RAHMANI MASHOUR,T.A.WHITE,J.KNOSKA,G.PENA AUTHOR 3 ESPERANZA,F.KOUA,A.TOLSTIKOVA,M.GROESSLER,P.FISCHER,V.HENNICKE, AUTHOR 4 H.FLECKENSTEIN,F.TROST,M.GALCHENKOVA,Y.GEVORKOV,C.LI,S.AWEL, AUTHOR 5 L.X.PAULRAJ,N.ULLAH,S.FALKE,B.ALVES FRANCA,M.SCHWINZER,H.BROGNARO, AUTHOR 6 N.WERNER,M.PERBANDT,H.TIDOW,B.SEYCHELL,T.BECK,S.MEIER,J.J.DOYLE, AUTHOR 7 H.GISELER,D.MELO,I.DUNKEL,T.J.LANE,A.PECK,S.SAOUANE,J.HAKANPAEAE, AUTHOR 8 J.MEYER,H.NOEI,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF,L.ZHANG,C.EHRT, AUTHOR 9 J.PLETZER-ZELGERT,J.WOLLENHAUPT,C.FEILER,M.WEISS,E.C.SCHULZ, AUTHOR 10 P.MEHRABI,B.NORTON-BAKER,C.SCHMIDT,K.LORENZEN,R.SCHUBERT,H.HAN, AUTHOR 11 A.CHARI,Y.FERNANDEZ GARCIA,D.TURK,R.HILGENFELD,M.RAREY,A.ZALIANI, AUTHOR 12 H.N.CHAPMAN,A.PEARSON,C.BETZEL,A.MEENTS REVDAT 6 06-NOV-24 7ARF 1 REMARK REVDAT 5 31-JAN-24 7ARF 1 JRNL REVDAT 4 19-MAY-21 7ARF 1 JRNL REVDAT 3 14-APR-21 7ARF 1 COMPND SOURCE JRNL REVDAT 2 09-DEC-20 7ARF 1 JRNL REVDAT 1 02-DEC-20 7ARF 0 JRNL AUTH S.GUNTHER,P.Y.A.REINKE,Y.FERNANDEZ-GARCIA,J.LIESKE,T.J.LANE, JRNL AUTH 2 H.M.GINN,F.H.M.KOUA,C.EHRT,W.EWERT,D.OBERTHUER,O.YEFANOV, JRNL AUTH 3 S.MEIER,K.LORENZEN,B.KRICHEL,J.D.KOPICKI,L.GELISIO,W.BREHM, JRNL AUTH 4 I.DUNKEL,B.SEYCHELL,H.GIESELER,B.NORTON-BAKER, JRNL AUTH 5 B.ESCUDERO-PEREZ,M.DOMARACKY,S.SAOUANE,A.TOLSTIKOVA, JRNL AUTH 6 T.A.WHITE,A.HANLE,M.GROESSLER,H.FLECKENSTEIN,F.TROST, JRNL AUTH 7 M.GALCHENKOVA,Y.GEVORKOV,C.LI,S.AWEL,A.PECK,M.BARTHELMESS, JRNL AUTH 8 F.SCHLUNZEN,P.LOURDU XAVIER,N.WERNER,H.ANDALEEB,N.ULLAH, JRNL AUTH 9 S.FALKE,V.SRINIVASAN,B.A.FRANCA,M.SCHWINZER,H.BROGNARO, JRNL AUTH10 C.ROGERS,D.MELO,J.J.ZAITSEVA-DOYLE,J.KNOSKA, JRNL AUTH11 G.E.PENA-MURILLO,A.R.MASHHOUR,V.HENNICKE,P.FISCHER, JRNL AUTH12 J.HAKANPAA,J.MEYER,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF, JRNL AUTH13 A.R.BECCARI,G.BOURENKOV,D.VON STETTEN,G.POMPIDOR,I.BENTO, JRNL AUTH14 S.PANNEERSELVAM,I.KARPICS,T.R.SCHNEIDER,M.M.GARCIA-ALAI, JRNL AUTH15 S.NIEBLING,C.GUNTHER,C.SCHMIDT,R.SCHUBERT,H.HAN,J.BOGER, JRNL AUTH16 D.C.F.MONTEIRO,L.ZHANG,X.SUN,J.PLETZER-ZELGERT, JRNL AUTH17 J.WOLLENHAUPT,C.G.FEILER,M.S.WEISS,E.C.SCHULZ,P.MEHRABI, JRNL AUTH18 K.KARNICAR,A.USENIK,J.LOBODA,H.TIDOW,A.CHARI,R.HILGENFELD, JRNL AUTH19 C.UETRECHT,R.COX,A.ZALIANI,T.BECK,M.RAREY,S.GUNTHER,D.TURK, JRNL AUTH20 W.HINRICHS,H.N.CHAPMAN,A.R.PEARSON,C.BETZEL,A.MEENTS JRNL TITL X-RAY SCREENING IDENTIFIES ACTIVE SITE AND ALLOSTERIC JRNL TITL 2 INHIBITORS OF SARS-COV-2 MAIN PROTEASE. JRNL REF SCIENCE V. 372 642 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 33811162 JRNL DOI 10.1126/SCIENCE.ABF7945 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.GUENTHER,P.Y.A.,REINKE,Y.,FERNANDEZ-GARCIA,J.,LIESKE,T.J., REMARK 1 AUTH 2 LANE,H.M.,GINN,F.H.M.,KOUA,C.,EHRT,W.,EWERT,D.,OBERTHUER,O., REMARK 1 AUTH 3 YEFANOV,S.,MEIER,K.,LORENZEN,B.,KRICHEL,J.D.,KOPICKI,L., REMARK 1 AUTH 4 GELISIO,W.,BREHM,I.,DUNKEL,B.,SEYCHELL,H.,GIESELER,B., REMARK 1 AUTH 5 NORTON-BAKER,B.,ESCUDERO-PEREZ,M.,DOMARACKY,S.,SAOUANE,A., REMARK 1 AUTH 6 TOLSTIKOVA,T.A.,WHITE,A.,HANLE,M.,GROESSLER,H.,FLECKENSTEIN, REMARK 1 AUTH 7 F.,TROST,M.,GALCHENKOVA,Y.,GEVORKOV,C.,LI,S.,AWEL,A.PECK,M., REMARK 1 AUTH 8 BARTHELMESS,F.,SCHLUENZEN,L.X.,PAULRAJ,N.,WERNER,H., REMARK 1 AUTH 9 ANDALEEB,N.,ULLAH,S.,FALKE,V.,SRINIVASAN,B.,FRANCA,M., REMARK 1 AUTH10 SCHWINZER,H.,BROGNARO,C.,ROGERS,D.,MELO,J.J.,DOYLE,J., REMARK 1 AUTH11 KNOSKA,G.E.,PENA MURILLO,A.,RAHMANI MASHHOUR,F.,GUICKING,V., REMARK 1 AUTH12 HENNICKE,P.,FISCHER,J.,HAKANPAEAE,J.,MEYER,P.,GRIBBON,B., REMARK 1 AUTH13 ELLINGER,M.,KUZIKOV,M.,WOLF,G.,BURENKOV,D.,VON STETTEN,G., REMARK 1 AUTH14 POMPIDOR,I.,BENTO,S.,PANNEERSELVAM,I.,KARPICS,T.R., REMARK 1 AUTH15 SCHNEIDER,M.,GARCIA ALAI,S.,NIEBLING,C.,GUENTHER,C.,SCHMIDT, REMARK 1 AUTH16 R.,SCHUBERT,H.,HAN,J.,BOGER,D.,MONTEIRO,L.,ZHANG,X.,SUN,J., REMARK 1 AUTH17 PLETZER-ZELGERT,J.,WOLLENHAUPT,C.,FEILER,M.,WEISS,E.C., REMARK 1 AUTH18 SCHULZ,P.,MEHRABI,K.,KARNICAR,A.,USENIK,J.,LOBODA,H.,TIDOW, REMARK 1 AUTH19 A.,CHARI,R.,HILGENFELD,C.,UETRECHT,R.,COX,A.,ZALIANI,T., REMARK 1 AUTH20 BECK,M.,RAREY,S.,GUENTHER,D.,TURK,W.,HINRICHS,H.N.,CHAPMAN, REMARK 1 AUTH21 A.,PEARSON,C.,BETZEL,A.MEENTS REMARK 1 TITL INHIBITION OF SARS-COV-2 MAIN PROTEASE BY ALLOSTERIC REMARK 1 TITL 2 DRUG-BINDING REMARK 1 REF BIORXIV 2020 REMARK 1 REFN ISSN 2692-8205 REMARK 1 DOI 10.1101/2020.11.12.378422 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.18-3855_9999 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 27.70 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 3 NUMBER OF REFLECTIONS : 17740 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.207 REMARK 3 R VALUE (WORKING SET) : 0.205 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.370 REMARK 3 FREE R VALUE TEST SET COUNT : 598 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 27.7000 - 3.1700 0.99 4333 150 0.1699 0.2122 REMARK 3 2 3.1700 - 2.5200 1.00 4302 149 0.2391 0.3060 REMARK 3 3 2.5200 - 2.2000 0.99 4264 146 0.2583 0.2929 REMARK 3 4 2.2000 - 2.0000 0.99 4243 153 0.3062 0.3677 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.267 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 34.519 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 39.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 53.77 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.009 2446 REMARK 3 ANGLE : 0.695 3327 REMARK 3 CHIRALITY : 0.051 374 REMARK 3 PLANARITY : 0.005 433 REMARK 3 DIHEDRAL : 5.062 340 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 6 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 1 THROUGH 43 ) REMARK 3 ORIGIN FOR THE GROUP (A): 7.6701 -10.6916 9.8882 REMARK 3 T TENSOR REMARK 3 T11: 0.4155 T22: 0.2483 REMARK 3 T33: 0.2897 T12: -0.0573 REMARK 3 T13: 0.0832 T23: 0.0036 REMARK 3 L TENSOR REMARK 3 L11: 4.1777 L22: 1.7661 REMARK 3 L33: 2.3114 L12: 0.5278 REMARK 3 L13: 0.9438 L23: 0.7963 REMARK 3 S TENSOR REMARK 3 S11: 0.1930 S12: -0.2485 S13: -0.1479 REMARK 3 S21: 0.2370 S22: -0.1933 S23: 0.2014 REMARK 3 S31: 0.5115 S32: 0.1385 S33: 0.0310 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 44 THROUGH 91 ) REMARK 3 ORIGIN FOR THE GROUP (A): 14.9798 -15.2610 23.3224 REMARK 3 T TENSOR REMARK 3 T11: 0.7230 T22: 0.4465 REMARK 3 T33: 0.4386 T12: -0.0421 REMARK 3 T13: 0.0177 T23: 0.0878 REMARK 3 L TENSOR REMARK 3 L11: 3.2756 L22: 2.8577 REMARK 3 L33: 2.1369 L12: 0.7332 REMARK 3 L13: 1.1202 L23: -0.1314 REMARK 3 S TENSOR REMARK 3 S11: 0.2379 S12: -0.4753 S13: -0.1869 REMARK 3 S21: 0.5104 S22: -0.1656 S23: 0.1173 REMARK 3 S31: 0.6651 S32: -0.3264 S33: -0.0468 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 92 THROUGH 155 ) REMARK 3 ORIGIN FOR THE GROUP (A): 10.0107 -5.4391 5.6095 REMARK 3 T TENSOR REMARK 3 T11: 0.3807 T22: 0.2931 REMARK 3 T33: 0.2734 T12: -0.0012 REMARK 3 T13: 0.0838 T23: 0.0534 REMARK 3 L TENSOR REMARK 3 L11: 3.5446 L22: 5.8666 REMARK 3 L33: 2.2415 L12: -0.7872 REMARK 3 L13: 2.5530 L23: -0.7198 REMARK 3 S TENSOR REMARK 3 S11: -0.0340 S12: 0.0171 S13: 0.2969 REMARK 3 S21: 0.1146 S22: -0.1549 S23: 0.1267 REMARK 3 S31: 0.2678 S32: 0.0687 S33: 0.2050 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 156 THROUGH 214 ) REMARK 3 ORIGIN FOR THE GROUP (A): 14.1953 4.1284 7.5978 REMARK 3 T TENSOR REMARK 3 T11: 0.2867 T22: 0.2741 REMARK 3 T33: 0.3411 T12: -0.0718 REMARK 3 T13: 0.0056 T23: 0.0480 REMARK 3 L TENSOR REMARK 3 L11: 1.8817 L22: 2.7308 REMARK 3 L33: 3.7816 L12: -0.3709 REMARK 3 L13: 0.9958 L23: -2.4520 REMARK 3 S TENSOR REMARK 3 S11: -0.1395 S12: 0.0480 S13: 0.2301 REMARK 3 S21: 0.3112 S22: -0.2439 S23: -0.2342 REMARK 3 S31: -0.4099 S32: 0.3632 S33: 0.3517 REMARK 3 TLS GROUP : 5 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 215 THROUGH 260 ) REMARK 3 ORIGIN FOR THE GROUP (A): 16.3525 18.0693 -11.4248 REMARK 3 T TENSOR REMARK 3 T11: 0.5618 T22: 0.5501 REMARK 3 T33: 0.4340 T12: -0.1608 REMARK 3 T13: -0.0026 T23: 0.1788 REMARK 3 L TENSOR REMARK 3 L11: 1.5595 L22: 1.3778 REMARK 3 L33: 2.7196 L12: -0.4629 REMARK 3 L13: -1.2939 L23: 0.9155 REMARK 3 S TENSOR REMARK 3 S11: -0.2050 S12: 0.6190 S13: 0.4109 REMARK 3 S21: -0.1108 S22: 0.3328 S23: -0.1560 REMARK 3 S31: -0.7717 S32: 0.4785 S33: -0.1452 REMARK 3 TLS GROUP : 6 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 261 THROUGH 302 ) REMARK 3 ORIGIN FOR THE GROUP (A): 8.5398 15.2336 -8.3581 REMARK 3 T TENSOR REMARK 3 T11: 0.3243 T22: 0.3965 REMARK 3 T33: 0.3966 T12: -0.0723 REMARK 3 T13: -0.0307 T23: 0.1787 REMARK 3 L TENSOR REMARK 3 L11: 4.5803 L22: 1.7363 REMARK 3 L33: 4.7463 L12: -0.1425 REMARK 3 L13: -0.3543 L23: 1.3031 REMARK 3 S TENSOR REMARK 3 S11: -0.1239 S12: 0.2169 S13: 0.3103 REMARK 3 S21: -0.1357 S22: -0.0720 S23: 0.0650 REMARK 3 S31: -0.4507 S32: 0.0445 S33: 0.1267 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7ARF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 25-OCT-20. REMARK 100 THE DEPOSITION ID IS D_1292111967. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-APR-20 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PETRA III, DESY REMARK 200 BEAMLINE : P11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0332 REMARK 200 MONOCHROMATOR : SI (111) SILICON CRYSTAL REMARK 200 OPTICS : KB-MIRROR SYSTEM REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17752 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 43.610 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 3.800 REMARK 200 R MERGE (I) : 0.05900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.05 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.7 REMARK 200 DATA REDUNDANCY IN SHELL : 3.60 REMARK 200 R MERGE FOR SHELL (I) : 1.07000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 6Y2E REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.37 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.93 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CO-CRYSTALLIZATION WITH THE COMPOUNDS REMARK 280 WAS ACHIEVED BY EQULIBRATING A 6.25 MG/ML PROTEIN SOLUTION IN 20 REMARK 280 MM HEPES BUFFER (PH 7.8) CONTAINING 1 MM DTT, 1MM EDTA, AND 150 REMARK 280 MM NACL AGAINST A RESERVOIR SOLUTION OF 100 MM MIB BUFFER (2:3:3 REMARK 280 MOLAR RATIO OF MALONIC ACID, IMIDAZOLE, AND BORIC ACID), PH 7.5, REMARK 280 CONTAINING 25% V/V PEG 1500 AND 5% V/V DMSO. PRIOR TO REMARK 280 CRYSTALLIZATION COMPOUND SOLUTIONS IN DMSO WERE DRIED ONTO THE REMARK 280 WELLS OF SWISSCI 96-WELL PLATES. TO ACHIEVE REPRODUCIBLE CRYSTAL REMARK 280 GROWTH SEEDING WAS USED. CRYSTALS APPEARED WITHIN A FEW HOURS REMARK 280 AND REACHED THEIR FINAL SIZE AFTER 2 -3 DAYS., VAPOR DIFFUSION, REMARK 280 SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 56.67300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 26.87850 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 56.67300 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 26.87850 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4010 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25320 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 CL CL A 404 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 VAL A 303 REMARK 465 THR A 304 REMARK 465 PHE A 305 REMARK 465 GLN A 306 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -132.37 53.13 REMARK 500 THR A 45 -148.61 -81.73 REMARK 500 ASN A 84 -116.34 54.76 REMARK 500 TYR A 154 -115.33 65.12 REMARK 500 HIS A 164 -56.92 -123.01 REMARK 500 HIS A 164 -56.73 -123.01 REMARK 500 REMARK 500 REMARK: NULL DBREF 7ARF A 1 306 UNP P0DTD1 R1AB_SARS2 3264 3569 SEQRES 1 A 306 SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS VAL SEQRES 2 A 306 GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR THR SEQRES 3 A 306 LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS PRO SEQRES 4 A 306 ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN PRO SEQRES 5 A 306 ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS ASN SEQRES 6 A 306 PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL ILE SEQRES 7 A 306 GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS VAL SEQRES 8 A 306 ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE VAL SEQRES 9 A 306 ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA CYS SEQRES 10 A 306 TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA MET SEQRES 11 A 306 ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN GLY SEQRES 12 A 306 SER CSD GLY SER VAL GLY PHE ASN ILE ASP TYR ASP CYS SEQRES 13 A 306 VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO THR SEQRES 14 A 306 GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE TYR SEQRES 15 A 306 GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA GLY SEQRES 16 A 306 THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP LEU SEQRES 17 A 306 TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU ASN SEQRES 18 A 306 ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL ALA SEQRES 19 A 306 MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS VAL SEQRES 20 A 306 ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE ALA SEQRES 21 A 306 VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU GLN SEQRES 22 A 306 ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA LEU SEQRES 23 A 306 LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG GLN SEQRES 24 A 306 CYS SER GLY VAL THR PHE GLN MODRES 7ARF CSD A 145 CYS MODIFIED RESIDUE HET CSD A 145 13 HET RVW A 401 23 HET DMS A 402 10 HET DMS A 403 10 HET CL A 404 1 HETNAM CSD 3-SULFINOALANINE HETNAM RVW (2~{S},3~{R},4~{R},5~{S},6~{S})-2-(HYDROXYMETHYL)-6- HETNAM 2 RVW SULFANYL-OXANE-3,4,5-TRIOL HETNAM DMS DIMETHYL SULFOXIDE HETNAM CL CHLORIDE ION HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE HETSYN RVW THIOGLUCOSE FORMUL 1 CSD C3 H7 N O4 S FORMUL 2 RVW C6 H12 O5 S FORMUL 3 DMS 2(C2 H6 O S) FORMUL 5 CL CL 1- FORMUL 6 HOH *97(H2 O) HELIX 1 AA1 SER A 10 GLY A 15 1 6 HELIX 2 AA2 HIS A 41 CYS A 44 5 4 HELIX 3 AA3 GLU A 47 ASN A 51 5 5 HELIX 4 AA4 ASN A 53 ARG A 60 1 8 HELIX 5 AA5 SER A 62 PHE A 66 5 5 HELIX 6 AA6 ILE A 200 GLY A 215 1 16 HELIX 7 AA7 THR A 226 TYR A 237 1 12 HELIX 8 AA8 THR A 243 LEU A 250 1 8 HELIX 9 AA9 LEU A 250 GLY A 258 1 9 HELIX 10 AB1 ALA A 260 GLY A 275 1 16 HELIX 11 AB2 THR A 292 GLY A 302 1 11 SHEET 1 AA1 7 VAL A 73 LEU A 75 0 SHEET 2 AA1 7 LEU A 67 ALA A 70 -1 N VAL A 68 O LEU A 75 SHEET 3 AA1 7 MET A 17 CYS A 22 -1 N GLN A 19 O GLN A 69 SHEET 4 AA1 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20 SHEET 5 AA1 7 VAL A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA1 7 VAL A 86 VAL A 91 -1 O LEU A 89 N VAL A 36 SHEET 7 AA1 7 VAL A 77 GLN A 83 -1 N GLN A 83 O VAL A 86 SHEET 1 AA2 5 LYS A 100 PHE A 103 0 SHEET 2 AA2 5 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA2 5 VAL A 148 ASP A 153 -1 N ASN A 151 O SER A 158 SHEET 4 AA2 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA2 5 SER A 121 ALA A 129 -1 O TYR A 126 N VAL A 114 SHEET 1 AA3 3 LYS A 100 PHE A 103 0 SHEET 2 AA3 3 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA3 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165 LINK C SER A 144 N CSD A 145 1555 1555 1.33 LINK C CSD A 145 N GLY A 146 1555 1555 1.33 LINK SG CYS A 156 S1 RVW A 401 1555 1555 2.02 CRYST1 113.346 53.757 44.607 90.00 102.14 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008823 0.000000 0.001898 0.00000 SCALE2 0.000000 0.018602 0.000000 0.00000 SCALE3 0.000000 0.000000 0.022931 0.00000